TBC1D29P
Putative TBC1 domain family member 29
Also known as: TBC29_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for TBC1D29P in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
150 residues, UniProt reviewed canonical sequence.
>Q9UFV1|TBC1D29P
1 MGHLDKEGLC TQGSSFSWLL RVLNDGISLG LTPCLWDMYL LEGEQMLMLI TSIAFKVQRS
61 LYEETNKETW GPATPRALKG TGRARPICES LHSSLQALTA SESSRGPSLL QTPPRVPGQQ
121 ALSRGDKGIS VSLSLPSLPS RRGRCGRIIGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TBC1D29P can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.6
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TBC1D29P as an antibody target. Whether an autoantibody or antibody against TBC1D29P could matter depends on whether native TBC1D29P is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TBC1D29P is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TBC1D29P as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...